Bempegaldesleukinum

Unassigned

New Medicines

Advanced renal cell carcinoma - first-line with nivolumab

Information

New molecular entity
Bristol-Myers Squibb
Bristol-Myers Squibb

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

CD122-biased agonist designed to stimulate the patient immune system to fight cancer. It allows the growth of specific cancer-killing T-cells (CD+8) and natural killer (NK) cells which are known as endogenous tumour-infiltrating lymphocytes (TILs).
UK incidence of RCC is 12 per 100,000 people. Patients with stage 1 (39%) and 2 (16%) RCC, and some with stage 3 (26%), are candidates for surgery. Five-year survival ranges from 40-90% in stage 1-3 disease, and 10% in stage 4.
Advanced renal cell carcinoma - first-line with nivolumab
Intravenous infusion

Unresectable or metastatic malignant melanoma - first-line in combination with nivolumab

Information

New molecular entity
Bristol-Myers Squibb
Bristol-Myers Squibb

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

CD122-biased agonist designed to stimulate the patient immune system to fight cancer. It allows the growth of specific cancer-killing T-cells (CD+8) and natural killer (NK) cells which are known as endogenous tumour-infiltrating lymphocytes (TILs).
In 2011, the UK age-standardised incidence of melanoma for females was 17.6 (11.7 in 2001) and for males 17.5 (10.1 in 2001) per 100,000 population [1].
Unresectable or metastatic malignant melanoma - first-line in combination with nivolumab
Intravenous infusion